Efficacy of efruxifermin in improving liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis/nonalcoholic steatohepatitis: a systematic review and meta-analysis of randomized controlled trials
Zain ul Abideen, Muhammad Hassan Waseem, Areeba Shoaib, Muhammad Osama et autres
In addition to demonstrating a predominant association with liver morbidity and mortality, metabolic dysfunction-associated steatohepatitis (MASH) constitutes a leading cause of liver transplantation. Efruxifermin, a bivalently linked fibroblast growth factor 21 analogue, inhibits fibrosis and protects hepatocytes from cellular distress. Although phase …
pk, us (code pays fourni par la source)